BioMed Research International

BioMed Research International / 2014 / Article

Letter to the Editor | Open Access

Volume 2014 |Article ID 930738 | 2 pages | https://doi.org/10.1155/2014/930738

18F-Fluorodeoxyglucose Uptake in Abdominal Aortic Aneurysms: A Useful Biomarker of AAA Rupture Risk

Academic Editor: Thomas Schmitz-Rixen
Received09 Aug 2014
Accepted19 Aug 2014
Published18 Sep 2014

Moris et al. discuss several emerging biomarkers implicated in the pathophysiology of abdominal aortic aneurysms (AAAs) [1]. These include biomarkers related to AAA extracellular matrix homeostasis or proteolysis, cellular or signalling pathways, proteins released by intraluminal thrombi, circulating cells and inflammation, metabolomics and genetic biomarkers. One emerging biomarker which probably also deserves to be mentioned is 18F-fluorodeoxyglucose (18F-FDG).

18F-FDG uptake detected by positron emission tomography (PET) is used to assess hypermetabolic activity of cells in tumors and inflammatory processes [2, 3]. Inflammation plays a key role in the development of AAAs [4]. AAA regions displaying increased 18F-FDG uptake show increased inflammatory activity and are enriched in leukocytes [5]. Increased 18F-FDG uptake in AAAs is associated with inflammation, aortic wall instability, and rupture risk [6]. Therefore, 18F-FDG uptake might be a new technique to study AAA disease in vivo and may improve prediction of AAA rupture risk [6, 7]. The prognostic value of 18F-FDG uptake was verified by a study reporting increased focal uptake of 18F-FDG in patients with large, rapidly expanding, or symptomatic AAAs that are prone to rupture [8].

In a recent study [9], biopsies of the AAA wall were obtained from regions with no 18F-FDG uptake and from regions positive for 18F-FDG uptake, both at the site positive for uptake and at a distant negative site of the AAA wall. The sites with a positive 18F-FDG uptake were characterized by a higher number of adventitial inflammatory cells and by a reduction of smooth muscle cells in the media compared with the negative 18F-FDG samples [9]. It was concluded that positive 18F-FDG uptake in the AAA wall is associated with an active inflammatory process and alterations of the expression of genes involved in the remodelling of adventitia and collagen degradation, which potentially participate in the weakening of the AAA wall preceding rupture [9]. Another use of 18F-FDG may be in endovascular AAA repair (EVAR) procedures [10]. Increased 18F-FDG uptake following EVAR may be an indirect predictor of AAA sac enlargement due to the presence of an endoleak (even if this is not detected by imaging modalities) and increased AAA rupture risk [10].

18F-FDG uptake may be a more promising biomarker for AAAs than some of those discussed by the authors (e.g., cystatin C and neutrophil gelatinase-associated lipocalin [NGAL]) [1]. There is evidence that NGAL and cystatin C are affected by kidney function, as well as by statins [1113]. In turn, patients with AAAs may have impaired kidney function and may well be on statins [14]. To make things even more complicated, statins can improve renal function in vascular patients [15]. These factors make the use of these markers subject to confounding.

In conclusion, 18F-FDG may prove to be a useful biomarker in the pathogenesis of AAAs. Future studies should investigate these possibilities.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

References

  1. D. Moris, E. Mantonakis, and E. Avgerinos, “Novel biomarkers of abdominal aortic aneurysm disease: identifying gaps and dispelling misperceptions,” BioMed Research International, vol. 2014, Article ID 925840, 13 pages, 2014. View at: Publisher Site | Google Scholar
  2. M. Miyagawa, R. Yokoyama, Y. Nishiyama, A. Ogimoto, J. Higaki, and T. Mochizuki, “Positron emission tomography-computed tomography for imaging of inflammatory cardiovascular diseases,” Circulation Journal, vol. 78, no. 6, pp. 1302–1310, 2014. View at: Publisher Site | Google Scholar
  3. B. Tantiwongkosi, F. Yu, A. Kanard, and F. R. Miller, “Role of (18)F-FDG PET/CT in pre and post treatment evaluation in head and neck carcinoma,” World Journal of Radiology, vol. 6, no. 5, pp. 177–191, 2014. View at: Google Scholar
  4. K. I. Paraskevas, M. Andrikopoulou, E. Anastasakis, D. Perrea, and D. P. Mikhailidis, “Oxidative stress in the pathogenesis of abdominal aortic aneurysms: a possible pathway for the effect of statins?” Angiology, vol. 61, no. 2, pp. 226–227, 2010. View at: Publisher Site | Google Scholar
  5. O. D. Defawe, R. Hustinx, J. O. Defraigne, R. Limet, and N. Sakalihasan, “Distribution of F-18 fluorodeoxyglucose (F-18 FDG) in abdominal aortic aneurysm: high accumulation in macrophages seen on PET imaging and immunohistology,” Clinical Nuclear Medicine, vol. 30, no. 5, pp. 340–341, 2005. View at: Publisher Site | Google Scholar
  6. C. Reeps, M. Essler, J. Pelisek, S. Seidl, H.-H. Eckstein, and B.-J. Krause, “Increased 18F-fluorodeoxyglucose uptake in abdominal aortic aneurysms in positron emission/computed tomography is associated with inflammation, aortic wall instability, and acute symptoms,” Journal of Vascular Surgery, vol. 48, no. 2, pp. 417–423, 2008. View at: Publisher Site | Google Scholar
  7. K. I. Paraskevas, A. A. Tzovaras, F. Gentimi, Z. S. Kyriakides, and D. P. Mikhailidis, “Predictors of abdominal aortic aneurysm (AAA) growth and AAA rupture risk besides AAA Size: fact or fiction?” Angiology, vol. 61, no. 4, pp. 321–323, 2010. View at: Publisher Site | Google Scholar
  8. N. Sakalihasan, H. Van Damme, P. Gomez et al., “Positron emission tomography (PET) evaluation of abdominal aortic aneurysm (AAA),” European Journal of Vascular and Endovascular Surgery, vol. 23, no. 5, pp. 431–436, 2002. View at: Publisher Site | Google Scholar
  9. A. Courtois, B. V. Nusgens, R. Hustinx et al., “18F-FDG uptake assessed by PET/CT in abdominal aortic aneurysms is associated with cellular and molecular alterations prefacing wall deterioration and rupture,” Journal of Nuclear Medicine, vol. 54, no. 10, pp. 1740–1747, 2013. View at: Publisher Site | Google Scholar
  10. K. I. Paraskevas, A. A. Tzovaras, V. Stathopoulos, F. Gentimi, and D. P. Mikhailidis, “Increased fluorodeoxyglucose uptake following endovascular abdominal aortic aneurysm repair: a predictor of endoleak?” The Open Cardiovascular Medicine Journal, vol. 4, pp. 117–119, 2010. View at: Publisher Site | Google Scholar
  11. S. M. Alharazy, N. Kong, R. Saidin et al., “Serum neutrophil gelatinase-associated lipocalin and cystatin C are early biomarkers of contrast-induced nephropathy after coronary angiography in patients with chronic kidney disease,” Angiology, vol. 65, no. 5, pp. 436–442, 2014. View at: Publisher Site | Google Scholar
  12. R. G. Fassett, I. K. Robertson, M. J. Ball, D. P. Geraghty, J. W. Cardinal, and J. S. Coombes, “Effects of atorvastatin on NGAL and cystatin C in chronic kidney disease: a post hoc analysis of the LORD trial,” Nephrology Dialysis Transplantation, vol. 27, no. 1, pp. 182–189, 2012. View at: Publisher Site | Google Scholar
  13. S. M. Alharazy, N. Kong, R. Saidin et al., “Neutrophil gelatinase-associated lipocalin as an early marker of contrast-induced nephropathy after coronary angiography,” Angiology, vol. 65, no. 3, pp. 216–223, 2014. View at: Publisher Site | Google Scholar
  14. K. I. Paraskevas, A. S. Wierzbicki, and D. P. Mikhailidis, “Statins and noncardiac vascular disease,” Current Opinion in Cardiology, vol. 27, no. 4, pp. 392–397, 2012. View at: Publisher Site | Google Scholar
  15. M. E. Alnaeb, F. Youssef, D. P. Mikhailidis, and G. Hamilton, “Short-term lipid-lowering treatment with atorvastatin improves renal function but not renal blood flow indices in patients with peripheral arterial disease,” Angiology, vol. 57, no. 1, pp. 65–71, 2006. View at: Publisher Site | Google Scholar

Copyright © 2014 Kosmas I. Paraskevas et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

795 Views | 343 Downloads | 2 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.